Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent ...
VAX-31, a 31-valent pneumococcal conjugate vaccine, showed robust immune responses and was well-tolerated in a Phase 1/2 study in adults aged 50 and older, with plans to advance to Phase 3 by mid-2025.
Reference News
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent ...
VAX-31, a 31-valent pneumococcal conjugate vaccine, showed robust immune responses and was well-tolerated in a Phase 1/2 study in adults aged 50 and older, with plans to advance to Phase 3 by mid-2025.